drugset / Trial / NCT00582634
Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
* To determine if docetaxel and cisplatin can be administered in a dose intense manner in the adjuvant setting in resected non-small cell lung cancer * To evaluate the time to progression and overall survival * To evaluate toxicities of this chemotherapy combination in the adjuvant setting * To correlate XPD and ERCC1 polymorphisms with time to progression and toxicities in patients treated with this regimen
Timeline
- Start
- 2004-09
- Primary completion
- 2007-12
- Completion
- 2007-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |